Loading
Sensus Healthcare, Inc. Stock: price and insider trades · United States
2 insiders bought €483k of shares over the last 90 days, the latest by Sachetta Eric, filed 31 Aug 2026.
Sensus Healthcare, Inc.: what insiders have been doing
Every trade that managers of Sensus Healthcare, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 23 October 2025 to 23 October 2026, the disclosure feed for Sensus Healthcare, Inc. logged 18 filings by 3 insiders.
No insider sold shares on the market over the period. Instead, the filings list 17 purchases totalling €622k, made by 3 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €111k, the purchase published on 31 August 2026 by Sachetta Eric is the largest of the period (0.25% of market cap). Among those who bought: 2 chief executives and 1 senior executive.
In all, 12 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 31 August 2026, 54 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 18 filings, this issuer sits below that mark. Since 2016, the database holds 31 purchases and 118 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 27.5 m USD of revenue and -7.7 m USD of net income.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
252
Thresholds
n/a
Buy Volume
€900,557
31 ops. · all time
Sell Volume
€7M
118 ops. · all time
Who traded when
BuySaleEric Sachetta10 buys
Michael Sardano7 buys
Joseph C. Sardano2 buys
Javier Rampolla1 buy
Since the insiders bought
- -17.4%Entry US$3.33 · Close 20 Oct 2026 US$2.75
- -18.2%Entry US$3.36 · Close 20 Oct 2026 US$2.75
- -30.0%Entry US$3.93 · Close 20 Oct 2026 US$2.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,144 of 26,286 companies
27.2
score / 100
Value28
Quality27
FCF yld0.7%
Earn yld-17%
EV/EBITDA·
ROE-35%
Gross mgn43%
Net mgn-28%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.75
Analyst consensus
4 analysts1.25/5
US$4.00Target US$5.38(+95%)US$6.00
Income statement
RevenueUS$27.5M
Gross profitUS$11.9M43% margin
EBITDA-US$9.7M-35% margin
Net income-US$7.7M-88.4% margin
Valuation
PER (forward)-15.9x
P/Book1.2x
Beta1.19
Balance sheet & cash
Market capUS$45.3M
Total debtUS$471k
Free Cash FlowUS$332k
Debt / Equity1%
Profitability & ownership
ROE-34.8%
ROA-16.5%
% insiders18.7%
% institutions27.7%
Last declaration on 31 August 2026
Declarations252 total
37,537 shares@ US$3.4370.25% mcap23.5% of flowCommon StockSEC:0002097345-26-000016:0
Canonical exit: 26 Nov 2026 (T+90)
27,304 shares@ US$3.5380.19% mcap17.7% of flowCommon StockSEC:0002097345-26-000016:1
Canonical exit: 29 Nov 2026 (T+90)
9,708 shares@ US$3.2890.062% mcap5.8% of flowCommon StockSEC:0002097345-26-000014:0
Canonical exit: 24 Nov 2026 (T+90)
10,925 shares@ US$3.1810.068% mcap6.3% of flowCommon StockSEC:0002097345-26-000014:1
Canonical exit: 25 Nov 2026 (T+90)
34,697 shares@ US$3.2540.22% mcap20.5% of flowCommon StockSEC:0002097345-26-000012:0
Canonical exit: 22 Nov 2026 (T+90)
24,000 shares@ US$3.1280.15% mcap13.6% of flowCommon StockSEC:0002097345-26-000010:0
Canonical exit: 18 Nov 2026 (T+90)
7,000 shares@ US$3.2540.044% mcap4.1% of flowCommon StockSEC:0002097345-26-000010:1
Canonical exit: 19 Nov 2026 (T+90)
20,000 shares@ US$3.02430.12% mcap3.1% of flowCommon StockSEC:0001300111-26-000002:0
Canonical exit: 18 Nov 2026 (T+90)
2,000 shares@ US$3.811.4% of flowCommon StockSEC:0002097345-26-000004:0
Canonical exit: 25 May 2026 (T+90)
40,000 shares0Common StockSEC:0001720602-25-000015:0
7,000 shares@ US$3.935.1% of flowCommon StockSEC:0002097345-25-000008:0
Canonical exit: 19 Feb 2026 (T+90)
2,500 shares@ US$4.502.1% of flowCommon StockSEC:0002097345-25-000006:0
Canonical exit: 11 Feb 2026 (T+90)
1,000 shares@ US$3.802.9% of flowCommon StockSEC:0001720602-25-000011:0
Canonical exit: 16 Feb 2026 (T+90)
25,000 shares@ US$4.035.2% of flowCommon StockSEC:0001300111-25-000005:0
Canonical exit: 16 Feb 2026 (T+90)
234 shares@ US$4.340.4% of flowCommon StockSEC:0001720602-25-000010:2
Canonical exit: 9 Feb 2026 (T+90)
766 shares@ US$4.271.2% of flowCommon StockSEC:0001720602-25-000007:1
Canonical exit: 9 Feb 2026 (T+90)
234 shares@ US$4.240.4% of flowCommon StockSEC:0001720602-25-000007:2
Canonical exit: 9 Feb 2026 (T+90)
1,000 shares@ US$4.263.2% of flowCommon StockSEC:0001720602-25-000004:0
Canonical exit: 9 Feb 2026 (T+90)
1,000 shares@ US$3.372.5% of flowCommon StockSEC:0001415889-25-021748:0
Canonical exit: 11 Nov 2025 (T+90)
1,000 shares@ US$5.955.0% of flowCommon StockSEC:0001415889-25-003440:0
Canonical exit: 11 May 2025 (T+90)
501 shares@ US$5.952.3% of flowCommon StockSEC:0001415889-25-003441:0
Canonical exit: 11 May 2025 (T+90)
20,000 shares0Common StockSEC:0001415889-24-029853:0
20,000 shares0Common StockSEC:0001415889-24-029865:0
40,000 shares0Common StockSEC:0001415889-24-029833:0
20,000 shares0Common StockSEC:0001415889-24-029866:0
25 of 252 declarations
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a US medical-device company listed on the Nasdaq market in the United States under the ticker SRTS. Headquartered in Boca Raton, Florida, the business was organized in 2010 and later completed its corporate conversion into Sensus Healthcare, Inc. in 2016. The company is highly focused: it designs, manufactures, and commercializes superficial radiation therapy (SRT) systems used primarily for non-melanoma skin cancers and, in certain cases, non-oncological dermatological conditions such as keloids. That narrow focus makes Sensus an interesting small-cap medtech name: it has a differentiated technology platform, but its investment case is highly sensitive to reimbursement, physician adoption, and customer concentration.
Its core product family consists of the SRT-100, SRT-100+, and SRT-100 Vision platforms. The SRT-100 Vision, also known as IG-SRT, integrates high-frequency ultrasound imaging into the treatment workflow to improve targeting and treatment planning. Beyond the hardware itself, Sensus has been building a broader clinical ecosystem around its devices, including workflow tools, records management, reimbursement support, and, since 2024, a healthcare-services subsidiary supporting dermatology clinics through equipment, radiation oncology oversight, physics oversight, and on-site technologist services under its “Fair Deal Agreement” model.
Read moreShow less
From a competitive standpoint, Sensus is best viewed as a niche specialist rather than a broad-based market leader. Its value proposition centers on a non-invasive, patient-friendly alternative to surgery that aims to reduce pain, scarring, and recovery time. Commercial success therefore depends not only on clinical performance, but also on the willingness of dermatology and oncology practices to adopt the technology, the strength of reimbursement, and the company’s ability to expand and retain its installed base. The company operates globally as a single reportable segment and sells through a distribution and marketing network, with exposure to the United States and select international markets, including China.
Recent developments have been important for the investment narrative. Throughout 2025 and into early 2026, Sensus highlighted improving reimbursement visibility, including the publication of dedicated CPT codes for superficial radiotherapy for non-melanoma skin cancer. Management has described this as a meaningful catalyst for customer activity, diversification, and eventual profitability. In February 2026, the company launched Sensus Link, a cloud-based software and connectivity solution designed to extend capabilities across its installed base. In first-quarter 2026 reporting, Sensus emphasized a cash balance of $18.3 million and no debt, which is notable for investors following this Nasdaq-listed United States medtech company.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
